文章摘要
裴氏温肾泄浊解毒汤配合血液透析治疗慢性肾衰的临床疗效研究
Study on the Clinical Efficacy of Pei"s Wenshen Xiezhuo Jiedu Decoction Combined with Hemodialysis in the Treatment of Chronic Renal Failure
DOI:
中文关键词: 慢性肾功能衰竭  脾肾阳虚和浊毒瘀阻证  裴氏温肾泄浊解毒汤  血液透析  肾功能  炎症因子  中医证候  安全性
英文关键词: Chronic renal failure  Spleen and kidney yang deficiency and turbidity toxin stasis syndrome  Pei"s Wenshen Xiezhuo Jiedu Decoction  Hemodialysis  Renal function  Inflammatory factors  TCM syndrome  Security
基金项目:甘肃省武威市科技计划自筹项目(WW25Z01SF042),
作者单位邮编
李应宏 甘肃省武威肿瘤医院 733000
魏金芬* 甘肃省武威肿瘤医院 
马瑞青 甘肃省武威肿瘤医院 
郝文婕 甘肃省武威肿瘤医院 
张宇杰 甘肃省武威肿瘤医院 
周学超 甘肃省武威肿瘤医院 
李霞 甘肃省武威肿瘤医院 
牛小蕊 甘肃省武威肿瘤医院 
摘要点击次数:
全文下载次数:
中文摘要:
      目的 探讨裴氏温肾泄浊解毒汤配合血液透析治疗脾肾阳虚、浊毒瘀阻证慢性肾功能衰竭(Chronic Renal Failure, CRF)的临床疗效,及其对患者肾功能、炎症因子及中医证候的影响。方法 选取2025年9月至2026年3月本院肾病科收治的80例脾肾阳虚、浊毒瘀阻证CRF患者作为研究对象,按照随机数字表法分为对照组和观察组,每组40例。对照组采用常规血液透析治疗,观察组在对照组基础上联合裴氏温肾泄浊解毒汤口服治疗。两组均连续治疗4周。比较两组临床疗效、治疗前后肾功能指标(血肌酐Scr、尿素氮BUN、尿酸UA、内生肌酐清除率Ccr)、炎症因子(TNF-α、IL-6、IL-10)、中医证候积分及不良反应发生率。结果 观察组的总有效率和显效率分别为97.50%和72.50%,显著高于对照组的72.50%和45.00%(P<0.05);治疗后,两组Scr、BUN、UA水平均显著降低,Ccr水平显著升高,且观察组改善幅度优于对照组(P<0.05);两组TNF-α、IL-6水平显著降低,IL-10水平显著升高,观察组优于对照组(P<0.05);观察组腰膝酸软、畏寒肢冷、神疲乏力、小便不利、肢体浮肿、恶心纳呆、腹胀、头晕耳鸣等中医证候改善显著优于对照组(P<0.05);两组不良反应发生率比较(P>0.05)。结论 裴氏温肾泄浊解毒汤配合血液透析治疗脾肾阳虚、浊毒瘀阻证CRF,可显著提升临床疗效,改善患者肾功能,调节炎症反应,缓解中医证候,且安全性良好。
英文摘要:
      Objective To investigate the clinical efficacy of Pei''s Wenshen Xiezhuo Jiedu Decoction combined with hemodialysis in the treatment of chronic renal failure ( CRF ) with spleen and kidney yang deficiency and turbidity toxin stasis syndrome, and its effect on renal function, inflammatory factors and TCM syndromes.Methods From September 2025 to March 2026, 80 CRF patients with spleen-kidney yang deficiency and turbidity-toxin stasis syndrome admitted to the Department of Nephrology of our hospital were selected as the research objects. According to the random number table method, they were divided into control group and observation group, with 40 cases in each group.The control group was treated with conventional hemodialysis, and the observation group was treated with Pei''s Wenshen Xiezhuo Jiedu Decoction on the basis of the control group. Both groups were treated continuously for 4 weeks. The clinical efficacy, renal function indexes (serum creatinine Scr, urea nitrogen BUN, uric acid UA, endogenous creatinine clearance rate Ccr), inflammatory factors (TNF-α, IL-6, IL-10), TCM syndrome scores and incidence of adverse reactions were compared between the two groups before and after treatment.Results The total effective rate and markedly effective rate of the observation group were 97.50 % and 72.50 % respectively, which were significantly higher than those of the control group ( 72.50 % and 45.00 % ) (P<0.05).After treatment, the levels of Scr, BUN and UA in the two groups were significantly decreased, and the level of Ccr was significantly increased, and the improvement of the observation group was better than that of the control group(P<0.05).The levels of TNF-α and IL-6 in the two groups were significantly decreased, and the level of IL-10 was significantly increased. The observation group was better than the control group(P<0.05).The improvement of TCM symptoms such as soreness and weakness of waist and knees, aversion to cold and cold limbs, lassitude, dysuria, limb edema, nausea and anorexia, abdominal distension, dizziness and tinnitus in the observation group was significantly better than that in the control group(P<0.05).The incidence of adverse reactions in the two groups was compared (P>0.05). Conclusion Pei''s Wenshen Xiezhuo Jiedu Decoction combined with hemodialysis in the treatment of CRF with spleen and kidney yang deficiency and turbidity toxin stasis syndrome can significantly improve the clinical efficacy, improve the renal function of patients, regulate the inflammatory response, alleviate the TCM syndrome, and has good safety.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭